Tags

Type your tag names separated by a space and hit enter

The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women.
Arch Intern Med. 1993 Jun 28; 153(12):1462-8.AI

Abstract

OBJECTIVE

To evaluate whether estrogen plus progesterone replacement therapy influences the plasma lipoprotein[a] (Lp[a]) levels in postmenopausal women.

DESIGN

Fifty-five women who had been menopausal for at least 1 year were followed up for 12 months. Twenty-four subjects served as the control group and 31 subjects served as the therapy group. The therapy consisted of conjugated estrogen (1.25 mg/d) and medroxyprogesterone acetate (10 mg/d for 10 days a month). Blood samples were obtained before the start of therapy and at 6 months and 12 months after therapy. Nine subjects in the therapy group were followed up for an additional year after the treatment was suspended (washout group).

SETTINGS

All subjects were healthy women (mean age, 52 years) who had natural menopause at least 1 year before the beginning of recruitment. None of the women had received exogenous sex steroids or drugs known to influence lipid and lipoprotein metabolism in the previous 12 months.

MAIN RESULTS

In the control group, no change was noted in the plasma Lp[a] concentrations during the study. In the treatment group, the mean plasma Lp[a] concentrations decreased 50% after 6 months (P < .01) and remained at this level 12 months after treatment was started. In the washout group, mean plasma Lp[a] levels tended to return to pretherapy values. In addition, estrogen plus progesterone treatment significantly lowered total cholesterol levels by 15% and low-density lipoprotein cholesterol levels by 30%; it increased high-density lipoprotein cholesterol levels by 19%.

CONCLUSION

The results suggest that in estrogen plus progesterone-treated postmenopausal women, the lipid profile is improved not only by lowering low-density lipoprotein cholesterol levels and raising high-density lipoprotein levels, but also by lowering plasma Lp[a] concentrations.

Authors+Show Affiliations

Institute of Pharmacological Sciences, University of Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8390232

Citation

Soma, M R., et al. "The Lowering of Lipoprotein[a] Induced By Estrogen Plus Progesterone Replacement Therapy in Postmenopausal Women." Archives of Internal Medicine, vol. 153, no. 12, 1993, pp. 1462-8.
Soma MR, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993;153(12):1462-8.
Soma, M. R., Osnago-Gadda, I., Paoletti, R., Fumagalli, R., Morrisett, J. D., Meschia, M., & Crosignani, P. (1993). The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Archives of Internal Medicine, 153(12), 1462-8.
Soma MR, et al. The Lowering of Lipoprotein[a] Induced By Estrogen Plus Progesterone Replacement Therapy in Postmenopausal Women. Arch Intern Med. 1993 Jun 28;153(12):1462-8. PubMed PMID: 8390232.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. AU - Soma,M R, AU - Osnago-Gadda,I, AU - Paoletti,R, AU - Fumagalli,R, AU - Morrisett,J D, AU - Meschia,M, AU - Crosignani,P, PY - 1993/6/28/pubmed PY - 1993/6/28/medline PY - 1993/6/28/entrez SP - 1462 EP - 8 JF - Archives of internal medicine JO - Arch Intern Med VL - 153 IS - 12 N2 - OBJECTIVE: To evaluate whether estrogen plus progesterone replacement therapy influences the plasma lipoprotein[a] (Lp[a]) levels in postmenopausal women. DESIGN: Fifty-five women who had been menopausal for at least 1 year were followed up for 12 months. Twenty-four subjects served as the control group and 31 subjects served as the therapy group. The therapy consisted of conjugated estrogen (1.25 mg/d) and medroxyprogesterone acetate (10 mg/d for 10 days a month). Blood samples were obtained before the start of therapy and at 6 months and 12 months after therapy. Nine subjects in the therapy group were followed up for an additional year after the treatment was suspended (washout group). SETTINGS: All subjects were healthy women (mean age, 52 years) who had natural menopause at least 1 year before the beginning of recruitment. None of the women had received exogenous sex steroids or drugs known to influence lipid and lipoprotein metabolism in the previous 12 months. MAIN RESULTS: In the control group, no change was noted in the plasma Lp[a] concentrations during the study. In the treatment group, the mean plasma Lp[a] concentrations decreased 50% after 6 months (P < .01) and remained at this level 12 months after treatment was started. In the washout group, mean plasma Lp[a] levels tended to return to pretherapy values. In addition, estrogen plus progesterone treatment significantly lowered total cholesterol levels by 15% and low-density lipoprotein cholesterol levels by 30%; it increased high-density lipoprotein cholesterol levels by 19%. CONCLUSION: The results suggest that in estrogen plus progesterone-treated postmenopausal women, the lipid profile is improved not only by lowering low-density lipoprotein cholesterol levels and raising high-density lipoprotein levels, but also by lowering plasma Lp[a] concentrations. SN - 0003-9926 UR - https://www.unboundmedicine.com/medline/citation/8390232/The_lowering_of_lipoprotein[a]_induced_by_estrogen_plus_progesterone_replacement_therapy_in_postmenopausal_women_ L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/vol/153/pg/1462 DB - PRIME DP - Unbound Medicine ER -